埃克替尼和培美曲塞联合顺铂一线治疗老年EGFR突变型晚期肺腺癌的临床观察  

The clinical observation of icotinib and pemetrexed combined cisplatin as first-line treatment for elderly patients with advanced EGFR mutation lungadenocarcinoma

作　　者：曹俊燕[1] 蔡方[1] 路月玲[1] 张之君[1] 王玉龙[1] Cao Junyan;Cai Fang;Lu Yueling;Zhang Zhijun;Wang Yulong(Department of Oncology,Taiyuan central hospital in Shanxi Province,Taiyuan 030009,China)

机构地区：[1]太原市中心医院肿瘤科,030009

出　　处：《山西医药杂志》2018年第10期1125-1127,共3页Shanxi Medical Journal

摘　　要：目的比较埃克替尼与培美曲塞联合顺铂一线治疗老年表皮生长因子受体(EGFR)突变晚期肺腺癌的近期疗效和毒副反应。方法选取我院2015年1月到2017年10月Ⅲ~Ⅳ期EGFR突变型肺腺癌患者24例,随机分为2组。对照组:培美曲塞500mg/m2静脉滴注第1天,顺铂75mg/m2静脉滴注第3~4天,21d为个周期,共4~6个周期。研究组:埃克替尼125mg,每日3次口服,直至疾病进展。评估2组的疗效及不良反应。结果对照组有效率50%,研究组有效率67%,2组比较差异无统计学意义。研究组不良反应发生率显著低于对照组,2组比较差异有统计学意义(P<0.05)。结论培美曲塞与埃克替尼一线治疗老年晚期EGFR基因突变的肺腺癌的疗效相当,埃克替尼不良反应较小,且服用方便。Objective To compare the curative efficacy and toxicity between icotinib and pemetrexed combined cisplatin as first-line treatment for elderly patients with advanced EGFR mutation lung adenocarcinoma.Methods According to the different treatment methods,24 cases of patients with advanced EGFR mutation elderly lung adenocarcinoma were divided into study group（n=12）and control group（n =12）.Patients in the study group were treated with icotinib,and patients in the control group were treated with pemetrexed combined cisplatin.The curative effect and the occurrence of adverse reactions of two group were compared.Results The effective rate of the control group is 50%,The effective rate of the study group is 67%.There was no statistically significant difference between the two groups.The occurrence of adverse reactions of the study group was significantly lower that of the control group（P 〈0.05）.Conclusion The curative effect of icotinib and pemetrexed combined cisplatin as first-line treatment for elderly patients with advanced EGFR mutation lung adenocarcinoma is equal.Icotinib has less adverse reactions and it is convenient for being taken.

关 键 词：埃克替尼 培美曲塞 顺铂 EGFR突变 肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]